Koo,

My sincerest apologies. I am guilty of not reading carefully myself. You were writing about Invokana (canagliflozin) and the CANVASS trial, not Jardiance (empagliflozin) and the EMPA-REG OUTCOME trial; both SGLT2 inhibitors. I'm glad your brought up Invokana. It was one of the rare examples of a company not issuing a top-line data release as all and just spilling all the beans at once at full data reveal. I think it was announced in this way because the Jardiance/empagliflozin CVOT results from EMPA-REG OUTCOME had already been reported 2 years prior and this was another drug in the same class. So not as much of a splash.

CANVAS and CANVAS-R for Invokana/canagliflozin SGLT2 inhibitor:

No top-line data reveal for CVOT study. CANVASS and CANVASS-R analyzed together and full data set published in NEJM and presented at ADA June 12, 2017

https://www.janssen.com/invokana-canagliflozin-significantly-reduces-combined-risk-cardiovascular-death-myocardial